Trinseo (NYSE: TSE), the global materials company and manufacturer of plastics, latex binders and synthetic rubber, will introduce a broadened medical portfolio when it exhibits at the COMPAMED trade show in Dusseldorf, Germany from November 14 – 17, 2016 at booth L39 in Hall 8B.
Trinseo continues to expand its plastics portfolio for medical applications beyond polycarbonate-based compounds to medical grade styrenics. This includes its newest plastic, STYRON™ 2678 MED Polystyrene Resin, a general purpose polystyrene (GPPS) offering the versatility of polystyrene with the assurance of biocompatibility and a three year extended notification of change. STYRON™ 2678 MED is ideal for clear packaging, diagnostic components, petri dishes and test kit housings.
Trinseo will continue to highlight its MAGNUM™ ABS Resins and EMERGE™ Advanced Resins for applications including single- and multiple-use drug delivery devices and equipment housings. The company’s ABS offers the advantage of mass polymerization technology which results in lower residual monomers, exceptional purity, brilliant whiteness, and lot-to-lot consistency.
“Companies need plastics that support today’s trends in medical device design such as light weighting, aesthetic appeal, durability and cost reduction,” said Wassim Berrak, European medical business manager. “Trinseo’s portfolio of biocompatible plastics ranging from transparent polystyrene to ABS to glass-filled polycarbonate to chemical resistant blends offers customers the variety they seek along with the ability to choose materials having very specific requirements, most cost effectively.”
Trinseo supports the medical market through its Consumer Essential Markets (CEM) unit, part of its Performance Plastics business. Last month, Trinseo achieved a milestone when it became ISO 13485 certified as “manufacturer and developer of medical compounds” at its medical production facilities in Stade, Germany and Hsinchu, Taiwan and also in ancillary functions including Research & Development, Technical Service & Development, Sales, Quality and Procurement. This certification indicates Trinseo’s commitment to the medical devices business and strategic alignment with its customers’ objectives.
Earlier this year the company introduced a new production and fulfillment model featuring custom medical compounding in Asia Pacific complementing medical compounding in North America and Europe. These facilities are sourced with polycarbonate base resins from Trinseo’s highest quality, medically-equivalent resins produced in Germany and also by its joint venture partner, Sumika Styron Polycarbonate Limited, in Japan.
To arrange a meeting with Trinseo onsite at COMPAMED 2016 contact Paula Biskup, global business communications manager.
Trinseo (NYSE: TSE) is a global materials solutions provider and manufacturer of plastics, latex binders, and synthetic rubber. We are focused on delivering innovative and sustainable solutions to help our customers create products that touch lives every day — products that are intrinsic to how we live our lives — across a wide range of end-markets, including automotive, appliances, consumer electronics, medical devices, electrical, building and construction, textile, paper and board, footwear and tires. Trinseo had approximately $4.4 billion in net sales in 2017, with 16 manufacturing sites around the world, and approximately 2,200 employees. For more information visit www.trinseo.com
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release may include, without limitation, forecasts of growth, revenues, business activity, acquisitions, financings and other matters that involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. As a result of the foregoing considerations, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.